Invitrocue currently operates in Singapore, Australia, China, Hong Kong and Germany,
and is listed on Australian Securities Exchange under the ticker IVQ.
Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases.
In 2016, the company expanded its work in liver disease to the field of oncology. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).About Us
News & Events
The 4th International Conference on Toxicity Testing Alternatives and Translational Toxicology & The 2nd Asian Congress on Alternatives @ Guangzhou
Date: October 11th, 2018; Thursday, Venue: Guangzhou Baiyun International Conference Center Prof Hanry Yu, co-founder of Invitrocue, will be giving a plenary presentation on: “Heterogeneity and solutions in cell-based models for in vitro toxicity testing applications”. Alternatives and translational toxicology have grown critically in modern toxicology and risk assessment. Meanwhile, alternatives are increasingly demanding for […]Read More
Oncology: The future of cancer treatment
Our international speakers will present the most important innovations and findings in the field of oncology. Happening on Monday, 1st October 2018, 9am – 3.45pm Venue: Klinikum rechts der Isar der Technischen Universität München Click to DownloadRead More
IVQ launches Personalised Cancer Screening Service Onco-PDO
Invitrocue launches world’s first commercial Personalised Cancer Screening Service: Onco-PDO™Read More
Invitrocue unveils novel cancer detection method, screens first customer in Singapore
Bio-analytic healthcare provider Invitrocue (ASX: IVQ), has advanced its proprietary cancer-detection test by screening its first commercial Onco-PDO customer in Singapore.Read More
Grant from Northern Ireland to commercialize Onco-PDO
Invitrocue secures grant from Northern Ireland to commercialise Onco-PDORead More